Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03641677
Recruitment Status : Active, not recruiting
First Posted : August 22, 2018
Last Update Posted : June 1, 2023
Information provided by (Responsible Party):
Lung Bioengineering Inc.

Brief Summary:
The objective of this study is to evaluate the safety and effectiveness of the CLES in enabling evaluation of potential donor lungs not otherwise used for transplant into subjects with end stage, survival-limiting lung disease in need of lung transplantation. This will be accomplished by evaluating subject survival at the later of 6 months or hospital discharge post-transplant.

Condition or disease Intervention/treatment Phase
Lung Diseases Device: Centralized Lung Evaluation System Procedure: Lung Transplant Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 174 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility
Actual Study Start Date : January 15, 2019
Estimated Primary Completion Date : December 26, 2023
Estimated Study Completion Date : March 18, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: EVLP Device: Centralized Lung Evaluation System
Assessment of allograft lung for transplant suitability

Procedure: Lung Transplant
Orthotopic single or double lung transplantation.

Active Comparator: Control Procedure: Lung Transplant
Orthotopic single or double lung transplantation.

Primary Outcome Measures :
  1. 12 month survival [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female;
  • Aged 18 years or older;
  • Informed consent is given for participation in the Study by the patient or patient's designated representative; and
  • Patient undergoes lung transplantation.

Exclusion Criteria:

  • Patients listed for same-side lung re-transplantation.
  • Patients listed for multiple organ transplantation including lung and any other organ.
  • Patients listed for live donor lobar lung transplant.
  • Patients positive for human immunodeficiency virus (HIV) or Burkholderia cenocepacia infection.
  • Patient receives a standard of care (non-EVLP) lung transplant but does not match to an EVLP subject based on the criteria for control matching.
  • Participating in another interventional trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03641677

Layout table for location information
United States, Florida
Mayo Clinic Florida
Jacksonville, Florida, United States, 32224
United States, Georgia
Emory University Hospital
Atlanta, Georgia, United States, 30322
United States, Maryland
University of Maryland Medical System
Baltimore, Maryland, United States, 21201
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
United States, Michigan
University of Michigan Medical Center
Ann Arbor, Michigan, United States, 48109
Spectrum Health
Grand Rapids, Michigan, United States, 49503
United States, New Jersey
Newark Beth Israel Medical Center
Newark, New Jersey, United States, 07112
United States, New York
NYU Langone Health
New York, New York, United States, 10016
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37204
United States, Virginia
INOVA Fairfax Hospital
Falls Church, Virginia, United States, 22042
Sponsors and Collaborators
Lung Bioengineering Inc.
Layout table for additonal information
Responsible Party: Lung Bioengineering Inc. Identifier: NCT03641677    
Other Study ID Numbers: EVP-DEV-LTX-301
First Posted: August 22, 2018    Key Record Dates
Last Update Posted: June 1, 2023
Last Verified: May 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Lung Bioengineering Inc.:
ex vivo lung perfusion
organ perfusion
centralized lung evaluation system
united therapeutics
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Respiratory Tract Diseases